27.48
Schlusskurs vom Vortag:
$25.50
Offen:
$24.88
24-Stunden-Volumen:
1.15M
Relative Volume:
3.91
Marktkapitalisierung:
$1.03B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+33.59%
1M Leistung:
+78.44%
6M Leistung:
+237.59%
1J Leistung:
-0.94%
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Firmenname
Oruka Therapeutics Inc
Sektor
Branche
Telefon
650-606-7910
Adresse
855 OAK GROVE AVE., MENLO PARK
Vergleichen Sie ORKA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ORKA
Oruka Therapeutics Inc
|
27.48 | 1.18B | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-22 | Eingeleitet | BTIG Research | Buy |
2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
2024-10-11 | Eingeleitet | Stifel | Buy |
2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
2024-09-17 | Eingeleitet | Leerink Partners | Outperform |
2024-09-16 | Eingeleitet | TD Cowen | Buy |
2024-09-13 | Eingeleitet | Jefferies | Buy |
2018-02-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
2013-10-09 | Eingeleitet | Dawson James | Buy |
Alle ansehen
Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten
Will Oruka Therapeutics Inc. stock outperform growth indexesDip Buying & Free Weekly Watchlist of Top Performers - newser.com
Will breakout in Oruka Therapeutics Inc. lead to full recovery2025 Short Interest & Long-Term Growth Portfolio Plans - newser.com
What high frequency data says about Oruka Therapeutics Inc.July 2025 Analyst Calls & Daily Technical Forecast Reports - newser.com
Will Oruka Therapeutics Inc. stock go up soon2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com
Barclays Initiates Oruka Therapeutics at Overweight With $48 Price Target - MarketScreener
Why Oruka Therapeutics Inc. stock attracts global investorsWeekly Trend Recap & Capital Efficient Trade Techniques - newser.com
ORKA: Barclays Initiates Coverage with Overweight Rating | ORKA Stock News - GuruFocus
Is Oruka Therapeutics Inc. stock supported by strong cash flows2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com
Is Oruka Therapeutics’ (ORKA) Fundraising Spree a Sign of Strategic Flexibility or Underlying Caution? - Sahm
Automated trading signals detected on Oruka Therapeutics Inc.Options Play & Safe Capital Investment Plans - newser.com
Oruka Therapeutics (NASDAQ:ORKA) Trading Up 7.5%Should You Buy? - MarketBeat
Oruka Therapeutics (ORKA) Is Up 33.2% After Announcing $1.25B Shelf Registration and $200M Offering - Yahoo Finance
Weiss Ratings Reiterates Sell (D-) Rating for Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: Exploring a Promising 66.83% Potential Upside - DirectorsTalk Interviews
How Oruka Therapeutics Inc. (HQ1) stock reacts to monetary easingBull Run & Weekly Top Gainers Trade List - newser.com
Why retail traders accumulate Oruka Therapeutics Inc. (HQ1) stockMarket Risk Summary & Daily Chart Pattern Signals - newser.com
How Oruka Therapeutics Inc. stock performs in stagflationLong Setup & Consistent Income Trade Ideas - newser.com
Can a trend reversal in Oruka Therapeutics Inc. lead to recoveryWeekly Stock Analysis & Community Consensus Picks - newser.com
What drives Oruka Therapeutics Inc stock priceMarket Entry Points & Budget Investment Success - earlytimes.in
Constellation Brands, Aehr Test Systems And 3 Stocks To Watch Heading Into Monday - Benzinga
How reliable is Oruka Therapeutics Inc. (HQ1) stock dividend growthSwing Trade & Advanced Technical Analysis Signals - newser.com
Should you wait for a breakout in Oruka Therapeutics Inc.Take Profit & Capital Efficiency Focused Ideas - newser.com
Oruka Therapeutics Inc Stock Analysis and ForecastValue Stock Picks & Free Real-Time Trading Alerts Every Day - earlytimes.in
Oruka Therapeutics files to sell 39.43M shares of common stock for holders - MSN
Oruka Therapeutics files for mixed shelf of upto $500 millionSEC filing - MarketScreener
Is Oruka Therapeutics Inc. forming a bottoming baseJuly 2025 Momentum & Risk Managed Investment Entry Signals - newser.com
Custom strategy builders for tracking Oruka Therapeutics Inc.2025 Analyst Calls & Daily Technical Forecast Reports - newser.com
What drives Oruka Therapeutics Inc HQ1 stock priceDividend Stability Analysis & Budget Friendly Growth - earlytimes.in
BTIG Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $56 - 富途牛牛
MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades - Stocktwits
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap UpWhat's Next? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Receives Buy Rating from BTIG Research - MarketBeat
Finanzdaten der Oruka Therapeutics Inc-Aktie (ORKA)
Es liegen keine Finanzdaten für Oruka Therapeutics Inc (ORKA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Oruka Therapeutics Inc-Aktie (ORKA) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Venrock Healthcare Capital Par | 10% Owner |
Feb 13 '25 |
Buy |
11.63 |
14,950 |
173,868 |
4,059,634 |
Venrock Healthcare Capital Par | 10% Owner |
Feb 12 '25 |
Buy |
11.86 |
8,971 |
106,396 |
4,044,684 |
Venrock Healthcare Capital Par | 10% Owner |
Feb 11 '25 |
Buy |
10.95 |
9,593 |
105,043 |
4,035,713 |
Venrock Healthcare Capital Par | 10% Owner |
Feb 10 '25 |
Buy |
10.90 |
574 |
6,257 |
4,026,120 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):